

UNCLASSIFIED

AD NUMBER
ADB282213
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Apr 2002. Other requests shall be referred to US Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702
AUTHORITY
USAMRMC ltr, 11 Mar 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-00-1-0688

TITLE: Analysis of Signaling Pathways Involved in Tumor
Promoting Functions of TGFbeta in Breast Cancer

PRINCIPAL INVESTIGATOR: Marcus D. Kretzschmar, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
New York, NY 10029

REPORT DATE: April 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Apr 02). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020910 071

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-1-0688
Organization: Mount Sinai School of Medicine

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Mome 8/12/02

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE April 2002	3. REPORT TYPE AND DATES COVERED Final (30 Sep 00 ~ 29 Mar 02)		
4. TITLE AND SUBTITLE Analysis of Signaling Pathways Involved in Tumor Promoting Functions of TGFbeta in Breast Cancer		5. FUNDING NUMBERS DAMD17-00-1-0688		
6. AUTHOR(S) Marcus D. Kretzschmar, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai School of Medicine New York, New York 10029 E-Mail: marcus.kretzschmar@mssm.edu		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES Report contains color.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Apr 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Transforming growth factor-β (TGFβ) is an important regulator of tumor growth and metastasis formation in breast carcinomas. TGFβ has a dual role in tumor progression, initially acting as a tumor suppressor by inhibiting the proliferation of normal epithelial cells and early stage tumor cells, and in later stages of the disease acting as a tumor promoter by inducing a more invasive tumor cell phenotype with elevated metastatic potential. This phenotypic change is often correlated with an epithelial-mesenchymal transition (EMT). The molecular basis for the switch in tumor cell responsiveness to TGFβ is mostly unclear. The importance of the Smad signaling pathway in mediating the growth inhibitory response to TGFβ in normal epithelial cells is well established. However, the TGFβ signaling events leading to EMT and enhanced tumorigenic properties are poorly understood. The aims of this project are to analyze these signaling events, and to identify novel signaling molecules that interact with TGFβ receptor complexes in invasive breast carcinoma cells. We have generated cell lines expressing different forms of the TGFβ receptor that are now being characterized and used for the isolation of receptor complexes from the plasma membrane. Preliminary data indicate the feasibility of this approach and identify candidate receptor interacting polypeptides.				
14. SUBJECT TERMS breast cancer, TGFbeta, signal transduction, epithelial-mesenchymal transition, receptor interacting polypeptides			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	
SF 298.....	2
Introduction.....	4
Body.....	5-8
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	10
Appendices.....	--

Final Report

Introduction.

The major cause of mortality in breast cancer is the formation of metastases, the spread of tumor cells to distant sites in the body via the lymph system or the bloodstream. The inhibition of metastasis formation is therefore an important goal for therapeutic intervention.

A critical regulator of breast tumor growth and metastasis is the transforming growth factor- β (TGF β). TGF β initially acts as a tumor suppressor by inhibiting the proliferation of normal epithelial cells and early stage tumor cells. During the course of the disease a switch in TGF β -responsiveness of the tumor cells often occurs. Instead of causing growth-inhibition TGF β can then induce the acquisition of a more invasive and tumorigenic cell phenotype with an elevated potential to form metastases. This phenotypic change is often correlated with an epithelial-to-mesenchymal transition (EMT). Together with effects of TGF β on stromal cells, the immune response, and the angiogenic process these direct actions on the tumor cells play a critical role in the promotion of malignant progression by TGF β . TGF β is abundantly expressed in most primary human breast tumors.

The molecular basis for the switch in tumor cell responsiveness is mostly unclear. It has been suggested, however, that a cooperation between TGF β and Ras signaling pathways is required [1]. TGF β regulates cellular processes via a signaling system that includes two distinct transmembrane receptor kinases, the type I receptor (T β R-I/Alk-5) and the type II receptor (T β R-II). Binding of TGF β to a T β R-II/T β R-I complex leads to the activation of the receptors and the propagation of the signal through phosphorylation of the cytoplasmic signaling mediators Smad2 and Smad3 by T β R-I. The importance of the SMAD signaling pathway in mediating the growth inhibitory response to TGF β in normal epithelial cells is well established. However, TGF β signaling events leading to EMT and enhanced tumorigenic properties in breast carcinoma cells are mostly unknown.

Based on previous studies using mammary epithelial cells as a model system I hypothesized that TGF β -induced EMT and gain of tumorigenic properties may depend on SMAD-independent TGF β signaling events [2]. The aims of the proposed project were to determine the contribution of SMAD-independent signaling to TGF β induction of EMT and gain of tumorigenic properties, and to identify novel signaling molecules that interact with TGF β receptor complexes in invasive breast carcinoma cells.

The potential significance of these studies relate to the multifunctional role of TGF β during tumor development and progression. This multifunctional role represents a major obstacle for the development of drugs aimed at manipulating TGF β functions in a beneficial way. It would be desirable to eliminate tumor promoting functions of TGF β without affecting its tumor suppressive functions. The identification of SMAD-independent signaling events involved in the tumor promoting actions will provide novel targets for the development of such selective drugs.

Studies and Results.

A growing body of genetic and biochemical evidence has accumulated suggesting that activated TGF β receptors signal through effector molecules that are activated independently of the SMAD signaling mediators and that elicit responses either with or without the cooperation of SMADs. These studies argue in favor of the hypothesis underlying the current project, namely that in human breast cancer cells a SMAD-independent TGF β signaling pathway may exist which is essential for TGF β -mediated induction of EMT and the gain of tumorigenic properties. This postulated pathway therefore may play a critical role in the tumor-promoting function of TGF β in breast cancer.

The evidence for SMAD-independent TGF β signaling includes the demonstration that Smad4-defective cell lines retain certain responsiveness to TGF β [3]. Furthermore, constitutively active forms of TGF β family receptors that all signal through the same subgroup of receptor-regulated SMADs can elicit distinct biological responses in various experimental systems, depending on the receptor utilized [4-6]. These experiments suggest that either the activation of SMADs by the various receptors is qualitatively different, possibly involving unknown receptor-specific interacting molecules, or that the receptors signal through additional, SMAD-independent and receptor-specific signaling pathways.

Recently it was reported that TGF β can induce the interaction of its receptor with the protein phosphatase 2A (PP2A), leading to subsequent association and inactivation of the p70^{S6} kinase [7]. This signaling pathway appears to function independently and in complementation to the SMAD pathway in the induction of cell cycle arrest. Finally, multiple studies have suggested that TGF β can signal through the mitogen-activated protein kinases (MAPKs) JNK and p38 [8-10]. However, the observed effects vary strongly in kinetics, magnitude, and MAPK subtype depending on the cell type and the experimental conditions used. The physiological relevance of these observations remains to be clarified.

We have investigated whether TGF β can activate MAPKs in the cell lines (i.e. EpH4 and EpRas) that are used as a model system for the analysis of TGF β signaling in non-transformed versus transformed mammary epithelial cells. As illustrated in a representative experiment TGF β was capable of activating JNK in EpH4 cells transiently and in a very rapid fashion, with a peak of activity at about 5 to 10 minutes post-TGF β treatment (Fig.1). This result supports the idea that TGF β signals through SMAD-independent mechanisms in mammary epithelial cells and that such mechanisms might play a role in TGF β -induced EMT and the acquisition of malignant properties in breast tumor cells. A biochemical link between MAPKs and the TGF β receptors has not been established to date.

We have made significant progress in the establishment of the stable cell lines that are key to the success of the project. All the necessary constructs were produced, utilizing both an eukaryotic expression vector (pCMV5) that is suitable for transient transfections and a retroviral vector (pBI) that is suitable for the establishment of stable cell lines. These constructs include the TGF β type I receptor (T β R-I/Alk-5) as a kinase-dead single point mutant, a constitutively-active single point mutant, or a double mutant. These receptor derivatives were tagged with a double Flag-epitope at their carboxy-terminal ends.

We have started the production of stable cell lines with the successful introduction of a retroviral vector (pRevTet-Off) into EpH4 cells that leads to the expression of a tetracycline-controlled transactivator (tTA). In the presence of tetracycline (or the analog doxycycline; Dox) in the growth medium tTA is inactive, while in the absence of the antibiotic tTA is active. Several independent cell clones were isolated and tested for Dox-dependent inducibility of a reporter construct that

contains a tTA-responsive promoter (Fig.2). Clone #9 was selected for further experiments based on its low basal activity in the presence of Dox and its strong (at least 50-fold) inducibility in the absence of Dox. Clone #9 was subsequently used to establish a number of stable cell lines that express the various mutant forms of the epitope-tagged TGF β receptor, either alone or in combination with a H-RasV12 oncogene. These cell lines are currently being characterized with respect to the inducibility and expression of the exogenous proteins.

In parallel to creating the stable cell lines we have established biochemical conditions for the affinity purification of epitope-tagged TGF β receptors. For this purpose COS cells were transiently transfected with the receptor expression constructs and the exogenous receptors were then immuno-affinity purified from whole cell lysates. Various detergents and buffer conditions were tested to obtain optimal conditions for the isolation of the receptor from cell cultures. Figure 3 shows an example of a receptor preparation obtained by this method and analyzed by SDS-PAGE and silverstaining. Several polypeptides appear to be co-purified in a receptor-specific fashion, indicating that they may represent receptor-interacting polypeptides. Whether these interactions are physiologically significant or a consequence of receptor overexpression in COS cells remains to be determined. Nevertheless, these preliminary results suggest that the biochemical approach taken in this project might be successful.

Furthermore, we are devising a method that will allow to separate the fraction of receptor that is present in the plasma membrane from the remaining fraction of receptor that is present in the endoplasmatic reticulum, the endosomes, or other intracellular compartments. This approach will ensure that identified polypeptides are likely to be signaling molecules that interact with the receptor in its plasma membrane location. This method uses covalent biotinylation of cell surface proteins, thereby allowing their streptavidin-mediated affinity purification subsequent to the initial Flag-epitope immuno-purification.

Using one of the stable cell lines that expresses exogenous Alk-5 we have now carried out first experiments to isolate the receptor for the identification of associated polypeptides. Analysis of the receptor preparation by SDS-PAGE and silverstaining revealed several polypeptides that appear to be specific for the receptor expressing cells (when compared to the parental control cells) (Fig. 4). We are now in the process of comparing the patterns of putative receptor-associated polypeptides among the different cell lines created, and to obtain sufficient material for the identification of polypeptides by mass spectrometry.

Another goal of our studies is the delineation of the structural motifs that are required for critical protein-protein interactions in the tumor-promoting response to TGF β in breast cancer cells. To dissect the structural requirements in T β R-I we are developing an assay system that will allow us to determine the domains of the receptor that are required for a particular cellular response, e.g. EMT. For this purpose adenoviral vectors were constructed that express either the kinase-dead mutant form of T β R-I or a constitutively-active form of T β R-I. Adenoviruses were produced that can efficiently infect EpH4 and EpRas cells, as visualized by the co-expression of the green fluorescent protein (GFP) (Fig. 5). The exogenous receptor is expressed in a similar time course upon virus infection (data not shown). Expression of activated T β R-I should allow to induce EMT (or other cellular responses) in the mammary epithelial cells and will therefore provide a system in which to delineate the structural requirements within the TGF β receptor.




Figure 1. Activation of JNK by TGFβ1 in mammary epithelial cells. EpH4 mammary epithelial cells were serum starved for 12h and then treated with TGFβ1 (50 pM) for the indicated times. Cells were lysed, endogenous JNK1 was immuno-precipitated with an α-JNK1 antibody (Santa Cruz Biotechnology), and *in vitro* kinase assays were performed using GST-Jun as a substrate. Kinase reactions were analyzed by SDS-PAGE and autoradiography. Aliquots of the same cell lysates were also subjected to SDS-PAGE and subsequent immuno-blotting with the α-JNK1 antibody and an HRP-conjugated secondary antibody. Blots were developed using ECL.




Figure 2. Inducibility of a tTA-responsive luciferase reporter gene in individual cell clones. EpH4 cells were stably transfected with a retroviral vector expressing the doxycycline regulated transactivator tTA. Several individual clones were selected and tested by transient transfection with a tTA responsive reporter gene and an internal control gene. Cells were then treated with or without Dox for 18 hrs, lysed, and luciferase activity was measured by luminometry. Normalized luciferase activity is blotted.




Figure 3. Immuno-purification of TβR-I via the Flag-epitope. COS cells were transiently transfected with an expression vector encoding the Flag-epitope tagged TGFβ receptor type I or the empty vector as a control. Two days post-transfection the cells were lysed and immuno-purification was carried out using anti-Flag monoclonal antibodies (M2) covalently coupled to agarose beads (Sigma). Bound material was eluted using Flag peptide and then analyzed by SDS-PAGE and silverstaining (A) and SDS-PAGE and anti-Flag immunoblotting (B). The arrows indicate the position of the main form of the tagged receptor.





Figure 4. Isolation of Alk-5 receptor associated polypeptides from stable cell lines. Mammary epithelial cell lines stably expressing an epitope-tagged form of the Alk-5 receptor were used to co-purify associated polypeptides. A cell line stably transfected with the empty vector was used as a control. Receptor preparations were analyzed by SDS-PAGE and silverstaining. The location of the full length Alk-5 receptor is indicated.

Figure 5. Infection of EpH4 mammary epithelial cells with GFP-expressing adenoviruses. EpH4 cells were grown in flasks up to a confluency of about 50% and then infected with recombinant adenoviruses that carry expression cassettes for the green fluorescence protein (GFP) and the TGF β type I receptor. Two days post-infection cells were analyzed by phase-contrast microscopy and photographed. The identical field of cells is shown for bright field and immuno-fluorescence microscopy.



Key research accomplishments.

- Establishment of mammary epithelial cell lines that express an epitope-tagged form of the TGF β receptor under tetracycline control
- Establishment of biochemical conditions for the isolation of TGF β receptor complexes from the plasma membrane of these cell lines
- Preliminary identification of polypeptides that copurify specifically with the TGF β receptor

Reportable outcomes.

Several mammary epithelial cell lines expressing various forms of epitope-tagged TGF β receptor have been generated and are currently being characterized and utilized for the identification of receptor-associated polypeptides.

Conclusions.

The growth factor TGF β plays an important role in the malignant progression of certain forms of carcinoma, including breast carcinoma. In tumor cells TGF β can cause epithelial-to-mesenchymal transition and the gain of tumorigenic and metastatic properties. The signaling events that mediate these functions of TGF β are poorly understood. The current project addresses the nature of these signaling events and attempts to identify and characterize the proteins that interact with TGF β receptors to initiate these critical events. The described results represent a significant step towards the successful completion of the project and suggest that the experimental approach taken will lead to important new discoveries. These discoveries have the potential of contributing to a new intellectual framework for the development of drugs that specifically target tumor promoting functions of TGF β in late stage breast cancer progression.

References.

1. Oft, M., et al., *TGF- β 1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells*. Genes Dev., 1996. 10: p. 2462-2477.
2. Kretzschmar, M., et al., *A mechanism of repression of TGF β /Smad signaling by oncogenic Ras*. Genes Dev., 1999. 13: p. 804-816.
3. Sirard, C., et al., *Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling*. J Biol Chem, 2000. 275(3): p. 2063-70.
4. Chen, D., et al., *Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages*. J. Cell. Biol., 1998. 142: p. 295-305.
5. Fujii, M., et al., *Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation*. Mol. Biol. Cell, 1999. 10: p. 3801-13.
6. Zou, H., et al., *Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage*. Genes Dev., 1997. 11: p. 2191-203.
7. Petritsch, C., et al., *TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest*. Genes Dev, 2000. 14(24): p. 3093-101.
8. Engel, M.E., et al., *Interdependent SMAD and JNK signaling in transforming growth factor- β -mediated transcription*. J. Biol. Chem., 1999. 274: p. 37413-20.
9. Hocevar, B.A., T.L. Brown, and P.H. Howe, *TGF- β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway*. EMBO J., 1999. 18: p. 1345-1356.
10. Sano, Y., et al., *ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling*. J. Biol. Chem., 1999. 274: p. 8949-8957.



DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

11 Mar 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB264655
ADB282172
ADB261548
ADB282212
ADB282747
ADB282213
ADB282133
ADB282748
ADB282793
ADB282229
ADB282720
ADB282132